|会社名||Edwards Lifesciences Corp （EW エドワ―ズライフサイエンス）|
|業種||先端医療機器_テクノロジ― 医療関連（Health Care）|
|概要||事業概要 エドワーズ・ライフサイエンス(Edwards Lifesciences Corporation)は欠陥心臓弁の置換、または修復に応用する心臓弁システムおよび修復製品の製造者である。同社は構造的心疾患および重症ケアのモニタリングなどの患者中心のイノベーションに従事する。同社のセグメントは米国、ヨーロッパ、日本、他の地域を含む。同社の製品分野は外科心臓弁療法、経カテーテル心臓弁、およびクリティカルケアを含む。同社は入院中の患者の心臓血管機能を測定するために使用される血行動態モニタリングシステムを提供する。同社の経カテーテル心臓弁製品は米国、シンガポール、スイスに生産される。クリティカルケア製品はプエルトリコとドミニカ共和国にある施設で生産される。同社の子会社はEdwards Lifesciences Asset Management Corporation、Edwards Lifesciences CardiAQ LLC.、 Valtech Cardio Inc.とRed Hill Insurance Corporationを含む。 エドワ―ズ・ライフサイエンスは重度の循環器疾患治療用の医療器具メ―カ―。心臓弁膜症などの循環器疾患や心臓血管疾患、また、救命救急診療技術、抹消血管障害の治療に焦点を置く。主要製品は、弁膜症治療用心臓弁｢カ―ペンタ―・エドワ―ズ・ペリマウント｣､人工弁輪、肺動脈カテ―テルなど。製品は約100カ国で販売される。 Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. Edwards Lifesciences is driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape.|
|本社所在地||One Edwards Way Irvine CA 92614 USA|
|代表者氏名||Michael A. Mussallem|
|代表者役職名||Chairman of the Board Chief Executive Officer|
|決算概要||決算概要 BRIEF: For the fiscal year ended 31 December 2018 Edwards Lifesciences Corp revenues increased 8% to $3.72B. Net income before extraordinary items decreased 16% to $738M. Revenues reflect Transcatheter Heart Valve Therapy segment increase of 13% to $2.29B Critical Care segment increase of 12% to $674.5M United States segment increase of 8% to $2.06B Rest of the world segment increase of 14% to $396M.|
Global Tissue Heart Valves Market Report- Industry Size, Share, Analysis, Opportunities and Forecast to 2025 | Edwards Lifesciences, Medtronic, Abbott 2021/07/11 07:44:09 Jumbo News
The research reports on Tissue Heart Valves Market report gives detailed overview of factors that affect global business scope. Tissue Heart Valves Market report shows the latest market insights with upcoming trends and breakdowns of products and services. This report provides statistics on the market situation, size, regions and growth factors. Tissue Heart Valves Market report contains 
Massive Growth of Transcatheter Mitral Valve Replacement Market by 2027 | Abbott Laboratories, Edwards Lifesciences, Micro Interventional Devices 2021/07/10 14:19:12 Tramways Monthly
Transcatheter Mitral Valve Replacement Market research report is the new statistical data source added by A2Z Market Research. It uses several approaches for analyzing the data of target market such as primary and secondary research methodologies. It includes investigations based on historical records, current statistics, and futuristic developments. The report gives a thorough overview of the 
The Daily Biotech Pulse: Lilly, Morphic''s Positive Data At ECCO, Humanigen''s COVID Treatment Gets Expedited Review In UK, TransCode IPO 2021/07/09 11:36:16 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO ) ( moved on positive analyst action) Ambrx Biopharma Inc. (NYSE: AMAM ) AtriCure, Inc. (NASDAQ: ATRC ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Edwards Lifesciences Corporation (NYSE: EW ) Novo Nordisk A/S (NYSE: NVO ) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 8) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) ADMA Biologics, Inc. (NASDAQ: ADMA ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) (announced positive Phase 2 data for non-alcoholic steatohepatitis drug) Allogene Therapeutics, Inc.
Clot Management Devices Market Overview, Size, Share Opportunities and Challenges By Major Players Teleflex, Edwards Lifesciences, Medtronic, Boston Scientific, Lemaitre Vascular, etc. 2021/07/09 08:32:09 Tramways Monthly
Up Market Research (UMR) announces the release of a new report, Clot Management Devices Market Research Report 2021. The statistics and insights provide an in-depth look into the market and opportunities. The report provides a comprehensive analysis of key market shares, size, trends, and forecasts for the global Clot Management Devices market. It also covers 
Global Patient Monitoring Devices Market Set to Hit New Highs: Expected to Reach USD 68.4 billion by 2027 2021/07/08 11:59:00 Intrado Digital Media
The leading players in the global patient monitoring devices market are Medtronic plc, Abbott Laboratories, Dragerwerk AG & Co. KGaA, Edwards Lifesciences Corporation, GE Healthcare, OMRON Corporation, Masimo Corporation, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Nihon Kohden Corporation, Natus Medical, Koninklijke Philips N.V., Getinge AB, Boston Scientific Corporation, Dexcom, Inc., Nonin Medical, Inc., Biotronik, Bio Telemetry, Inc., Schiller AG, F. Hoffmann-La Roche Ltd., Hill- Rom Holdings, Inc., and other prominent players. The leading players in the global patient monitoring devices market are Medtronic plc, Abbott Laboratories, Dragerwerk AG & Co. KGaA, Edwards Lifesciences Corporation, GE Healthcare, OMRON Corporation, Masimo Corporation, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Nihon Kohden Corporation, Natus Medical, Koninklijke Philips N.V., Getinge AB, Boston Scientific Corporation, Dexcom, Inc., Nonin Medical, Inc., Biotronik, Bio Telemetry, Inc., Schiller AG, F.
EWs BINGE: The Fast Saga, Episode 8 - Nathalie Emmanuel 2021/06/18 12:28:13 One News Page
Entertainment Weekly''s Derek Lawrence and Chanelle Berlin Johnson chat with Nathalie Emmanuel about The Fate of the Furious and its impact on the iconic Fast saga.
EastWest Bank investing heavily in digital initiatives 2021/06/16 16:00:00 Philstar Global
The Gotianun family is investing heavily in the digitalization of its banking arm East West Banking Corp. as Filipinos turn to electronic channels amid the pandemic.
ew report reinforces need for climate act - McGuigan 2021/06/16 11:40:50 Sinn Fein
Sinn Féin MLA Philip McGuigan has said the latest report from the Climate Change Committee reinforces the need for a climate change act.
Edwards Lifesciences Stock Gets Revived With Relative Strength Rating Upgrade 2021/06/15 17:52:00 Investor''s Business Daily
Edwards Lifesciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Edwards Lifesciences Corp (EW) Chairman & CEO Michael A Mussallem Sold $3.2 million of Shares 2021/06/11 00:15:07 GuruFocus
Related Stocks: EW ,
GOLDMAN SACHS: Buy these 24 high-growth stocks that are investing in cash cows for the future at the highest rates in the S&P 500 2021/05/04 14:54:00 Business Insider
Summary List Placement Investing in growth stocks can be a difficult game at the moment. Many have unthinkably high valuations thanks to things like low interest rates and heightened speculation, raising questions about how long their outperformance can last going forward. On the other hand, investing solely based on valuation isn't always necessarily the best approach either. Another way to identify companies that could do well in the future is by looking at how much they're investing in themselves and planting the seeds of future growth. In a recent note, a team of analysts at Goldman Sachs did just that, and came up with a list of firms outperforming the S&P 500 average in terms of investment for the future. To do so, they looked at how much a firm is investing in the future as a percentage of their operating cash flow while also factoring in asset depreciation. "High capex spending by itself can be a flawed measure of investment for future growth since many firms operate in asset-heavy industries and may barely invest at a rate faster than assets are depreciating," Goldman's Chief US Equity Strategist David Kostin said in the Monday note.
Neurovascular Thrombectomy Devices Market Expected to Rise by a CAGR of 14.27% by 2026, Estimates DelveInsight 2021/04/26 17:30:00 Benzinga
LAS VEGAS , April 26, 2021 /PRNewswire/ -- DelveInsight's " Neurovascular Thrombectomy Devices Market and Competitive Insight Report " provides the current and forecast market and comprises Neurovascular Thrombectomy Devices market trends and key competitors. DelveInsight estimated the market to rise at a high CAGR over the study period of 2018 – 2026. Key Highlights of Neurovascular Thrombectomy Devices Market report : Thrombectomy is a procedure to reduce the blood clots in the blood vessels. These devices are used to treat the brain's blockage, which may occur for many reasons, such as atheroma and thrombus in one or more arteries. Stroke is the leading cause of disability, and 80% to 85% of stroke cases are ischemic . The blood clot may cause fatal complications if left untreated, as per the World Health Organization (WHO) . Mechanical Thrombectomy is one of the treatment procedure needed to treat ischemic stroke patients using neurovascular thrombectomy devices such as aspiration catheters or stent retrieval, or a combination of both.
Leerink Partners Stick to Their Buy Rating for Edwards Lifesciences By Investing.com 2021/04/22 12:04:46 Investing.com
Leerink Partners Stick to Their Buy Rating for Edwards Lifesciences
Edward Lifesciences Hits Record High After Earnings Beat, TAVR Forecast - TheStreet 2021/04/21 14:42:18 The Street
Edwards Lifesciences said its sees transcatheter aortic valve replacement (TAVR) sales rising as high as 20% this year.
Cutting-edge firm with major Limerick plans hailed as ‘Great Place to Work’ 2021/03/02 13:00:00 Limerick Leader
A FIRM which provides innovations for structural heart disease has received a top certification. Edwards Lifesciences Corporation, which currently employs 165 people in Shannon, and will ramp up to 600 staff when it opens its permanent facility in the National Technology Park, has received the Great